Drugs / SL-901
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05382936 | Mar 2021 → May 2023 | neoplasm | Stemline Therapeutics, Inc. | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SL-901 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05382936 ↗ |
| Action | Inhibit | “PI3K Inhibitor SL-901” NCT05382936 ↗ |
| Route | Oral | “orally administered SL-901” NCT05382936 ↗ |